Contact
searchSearch
HMP Global
Login

Advertisement

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

Expert Insights

Cynthia Ma, MD; Neelima Vidula, MD; Seth Wander, MD
Videos
Selecting Chemotherapy for Patients With ER-Positive Early Breast Cancer
11/30/2023

Featuring Cynthia Ma, MD; Neelima Vidula, MD; and Seth Wander, MD

Featuring Cynthia Ma, MD; Neelima Vid...
Cynthia Ma, MD, leads part 1 of a 4-part roundtable panel discussion with Neelima Vidula, MD, and Seth Wander, MD, in which the panelists discuss considerations for selecting chemotherapy as a treatment option for patients with ER-positive...
Cynthia Ma, MD, leads part 1 of a 4-part roundtable panel discussion with Neelima Vidula, MD, and Seth Wander, MD, in which the panelists discuss considerations for selecting chemotherapy as a treatment option for patients with ER-positive...
Cynthia Ma, MD, leads part 1 of...
11/30/2023
Oncology
Gilles Salles, MD, PhD
Videos
Evaluating the Addition of Ibrutinib to Standard Chemotherapy for Follicular Lymphoma or MZL
11/27/2023

Featuring Gilles Salles, MD, PhD

Featuring Gilles Salles, MD, PhD ...
Gilles Salles, MD, PhD, highlights findings from the phase 3 SELENE trial, which aimed to assess the value of adding ibrutinib to chemotherapy among patients with previously treated follicular lymphoma or marginal zone lymphoma.
Gilles Salles, MD, PhD, highlights findings from the phase 3 SELENE trial, which aimed to assess the value of adding ibrutinib to chemotherapy among patients with previously treated follicular lymphoma or marginal zone lymphoma.
Gilles Salles, MD, PhD,...
11/27/2023
Oncology
Abhay Singh, MD
Videos
Minimizing Risk of Adverse Events and Transformation Among Patients With Follicular Lymphoma
11/27/2023

Featuring Abhay Singh, MD

Featuring Abhay Singh, MD
Abhay Singh, MD, shares advice for fellow oncologists treating patients with follicular lymphoma aiming to minimize the risk of adverse events and disease transformation to AML/MDS.
Abhay Singh, MD, shares advice for fellow oncologists treating patients with follicular lymphoma aiming to minimize the risk of adverse events and disease transformation to AML/MDS.
Abhay Singh, MD, shares advice...
11/27/2023
Oncology
Juergen C. Becker, MD, PhD
Conference Coverage
Avelumab Plus Cetuximab for Advanced Cutaneous Squamous Cell Carcinoma
11/20/2023

Featuring Juergen C. Becker, MD, PhD

Featuring Juergen C. Becker, MD, PhD ...
Juergen C. Becker, MD, PhD, German Cancer Consortium, discusses preliminary findings from the phase 2 AliCe study combining avelumab with cetuximab for patients with advanced, unresectable cutaneous squamous cell carcinoma.
Juergen C. Becker, MD, PhD, German Cancer Consortium, discusses preliminary findings from the phase 2 AliCe study combining avelumab with cetuximab for patients with advanced, unresectable cutaneous squamous cell carcinoma.
Juergen C. Becker, MD, PhD,...
11/20/2023
Oncology
Arlene Siefker-Radtke, MD, MD Anderson Cancer Center
Videos
Erdafitinib Shows Similar OS to Pembrolizumab Among Patients With FGFR-Altered Advanced/Metastatic Urothelial Carcinoma
11/16/2023

Featuring Arlene Seifker-Radtke, MD

Featuring Arlene Seifker-Radtke, MD ...
Arlene Siefker-Radtke, MD, discusses the THOR trial which found that erdafitinib had a similar OS to pembrolizumab among patients with advanced or metastatic urothelial carcinoma.
Arlene Siefker-Radtke, MD, discusses the THOR trial which found that erdafitinib had a similar OS to pembrolizumab among patients with advanced or metastatic urothelial carcinoma.
Arlene Siefker-Radtke, MD,...
11/16/2023
Oncology
Sara Lonardi, MD, Veneto Institute of Oncology
Videos
Using Liquid Biopsy to Guide Post-Surgical Treatment Among Patients With Colon Cancer
11/16/2023

Featuring Sara Lonardi, MD

Featuring Sara Lonardi, MD
Sara Lonardi, MD, shares results from the PEGASUS trial which found post-surgical liquid biopsy may be used to guide the clinical management of patients with high-risk stage II or stage III colon cancer.
Sara Lonardi, MD, shares results from the PEGASUS trial which found post-surgical liquid biopsy may be used to guide the clinical management of patients with high-risk stage II or stage III colon cancer.
Sara Lonardi, MD, shares results...
11/16/2023
Oncology
Jia Ruan, MD, PhD
Videos
Evaluating Prognostic Factors for Mantle Cell Lymphoma
11/15/2023

Featuring Jia Ruan, MD, PhD

Featuring Jia Ruan, MD, PhD
Jia Ruan, MD, PhD, discusses important factors to consider in determining mantle cell lymphoma prognosis, including the utilization of measurement tools like MIPI and genetic mutation profile data.
Jia Ruan, MD, PhD, discusses important factors to consider in determining mantle cell lymphoma prognosis, including the utilization of measurement tools like MIPI and genetic mutation profile data.
Jia Ruan, MD, PhD, discusses...
11/15/2023
Oncology
Colleen McCormick, MD, MPH
Videos
New and Emerging Targeted Therapies for Relapsing Ovarian Cancer
11/15/2023

Featuring Colleen McCormick, MD, MPH

Featuring Colleen McCormick, MD, MPH ...
At the Great Debates & Updates in Women’s Oncology meeting, Colleen McCormick, MD, MPH, gave an overview of new targeted therapies for patients with relapsing platinum-sensitive and platinum-resistant ovarian cancer.
At the Great Debates & Updates in Women’s Oncology meeting, Colleen McCormick, MD, MPH, gave an overview of new targeted therapies for patients with relapsing platinum-sensitive and platinum-resistant ovarian cancer.
At the Great Debates & Updates...
11/15/2023
Oncology
Kohei Shitara, MD, PhD, National Cancer Center Hospital East
Videos
Perioperative Pembrolizumab Plus Chemotherapy for Resectable Gastric or Gastroesophageal Junction Cancer
11/14/2023

Featuring Kohei Shitara, MD, PhD

Featuring Kohei Shitara, MD, PhD ...
In the KEYNOTE-585 study, perioperative pembrolizumab plus chemotherapy improved the pathological complete response among patients with locally advanced, resectable gastric or gastroesophageal (G/GEJ) cancer, but not the event-free survival.
In the KEYNOTE-585 study, perioperative pembrolizumab plus chemotherapy improved the pathological complete response among patients with locally advanced, resectable gastric or gastroesophageal (G/GEJ) cancer, but not the event-free survival.
In the KEYNOTE-585 study,...
11/14/2023
Oncology
Shernan Holtan, MD
Videos
Latest Updates in Graft-Versus-Host Disease Prophylaxis
11/13/2023

Featuring Shernan Holtan, MD

Featuring Shernan Holtan, MD
Shernan Holtan, MD, explores the most recent data in terms of graft-versus-host-disease prophylaxis.
Shernan Holtan, MD, explores the most recent data in terms of graft-versus-host-disease prophylaxis.
Shernan Holtan, MD, explores the...
11/13/2023
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Recent News

News
Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation
08/08/2024
Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.
Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.
Results from a phase 2 study...
08/08/2024
Oncology
FDA Approval
FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma
08/08/2024
The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.
The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.
The US Food and Drug...
08/08/2024
Oncology
News
Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer
08/07/2024
According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.
According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.
According to results from the...
08/07/2024
Oncology
News
Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL
08/07/2024
A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.
A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.
A recent study demonstrated that...
08/07/2024
Oncology
News
Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer
08/07/2024
Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.
Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.
Results from a phase 2 study...
08/07/2024
Oncology
FDA Approval
FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma
08/06/2024
Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.
Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.
Based on results from the INDIGO...
08/06/2024
Oncology
FDA Approval
FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma
08/02/2024
On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...
On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...
On August 2, 2024, the US Food...
08/02/2024
Oncology
FDA Approval
FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer
08/01/2024
The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.
The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.
The FDA approved dostarlimab...
08/01/2024
Oncology
News
Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML
08/01/2024
The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.
The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.
The first-line combination of...
08/01/2024
Oncology
News
Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas
08/01/2024
In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...
In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...
In the phase 1 trial, the...
08/01/2024
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use

Advertisement

Advertisement